Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Rhabdomyosarcoma, Alveolar × BAY 1895344 × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Lymphoid 1

Conditions

Sarcoma, Ewing 1 Rhabdomyosarcoma, Alveolar 1 Lymphoma 1

Interventions

ganitumab 1 efineptakin alfa 1 Receptor Protein-Tyrosine Kinases 1 Dasatinib 1 BAY 1895344 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05071209 2026-01-23

Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting

31 enrolled 14 charts

LymphoidSarcoma

Lymphoma, Sarcoma, Ewing, Rhabdomyosarcoma, Alveolar

Data powered by HemOnc (CC BY 4.0) Colophon ⚡